AXNX News and Press, Axonics Modulation Technologies Inc. From 11/07/21

Axonics, Inc. (AXNX) Q3 2021 Earnings Conference Call November 4, 2021 16:30 ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer & Director Dan Dearen - President & Chief Financial Officer Conference Call Participants A...

Image source: The Motley Fool. Axonics Modulation Technologies Inc (NASDAQ: AXNX) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Axonics Modulation Technologies Inc (AXNX) Q3 2021 Earni...

Gainers: Ontrak (NASDAQ:OTRK) +29%. BigCommerce Holdings (NASDAQ:BIGC) +17%. Farmer Brothers Company (NASDAQ:FARM) +17%. JFrog (NASDAQ:FROG) +13%. Expedia Group (NASDAQ:EXPE) +11%. Losers: Peloton Interactiv (NASDAQ:PTON) -26%. Applied Optoelectronics (NASDA...

Axonics Modulation Technologies (NASDAQ:AXNX): Q3 GAAP EPS of -$0.38 beats by $0.05. Revenue of $46.91M (+33.1% Y/Y) misses by $1.48M. Shares -8.08%. Press Release For further details see: Axonics Modulation Technologies EPS beats by $0.05, misses on revenue

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the third quarter ended September 30, 2021. “We are pleased with th...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has been named by the Orange County Business Journal as the fastest growing publicly traded company in Orange C...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2021 financial results after the market closes on Thursday, November 4, 2021. In conj...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued fi...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued fi...

Axonics (NASDAQ: AXNX) specializes in making medical devices to treat bladder and bowel dysfunction. It's the type of therapy that may be embarrassing to some, but the company's financial performance is nothing to be ashamed of. On Monday, the stock hit its 52-week high of $74.4...